|
||
|
| Home |  |
Firm Description | |
Sectors Covered | |
Completed Transactions | |
Testimonials | |
Principals | |
M&A Report and Publications |
|
Contact Us | |
| Acquiring Party | TPG Capital and the CPP Investment Board, private investment firms. |
|---|---|
| Transferring Party | IMS Health Inc. (NYSE:RX), a provider of market intelligence to the pharmaceutical and healthcare industries |
| Sector | Data Management/ Healthcare IT |
| Date | November 5, 2009 |
| Analysis Deemed a "Barbarians at the Gate" transaction, this mega deal marks a return of the "good old days" of huge credits backing private equity purchases of huge companies. IMS is the key source of critical data for the pharmaceutical and other healthcare sectors. In 09, IMS announced that it was exploring several strategic alternatives, assumedly related to its recent YOY 3Q losses in revenues and profits. IMS adopted a restructuring plan to streamline its operations, improve productivity segments, reduce capacity and align the size of its sales and management consulting teams in low demand areas, and focus on high-value, strategic growth areas. This deal seems a part of developing a new direction. Deal value -- $5.2b, on sales of $2.3b. | |
The Walden Group is a leading healthcare investment banking firm specializing in mergers, acquisitions and strategic transactions. It also invests its own funds and, together with its expert operational partners, provides value-added services to help special companies reach critical milestones. This information is copyright © 2004-2010 The Walden Group, Inc. This information is provided as a service to the public but remains the intellectual property of The Walden Group, Inc and may not be reproduced in any manner without the written permission of The Walden Group, Inc. The information contained in the transactions table was derived from publicly available and other sources. Transaction analysis and other information are based, in part, upon public comments, Walden Group research and judgments, and reporting and research of others. The information is not intended to be relied upon as pronouncements by the transaction participants or for any other reason. | |